Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
2023 | Another prognostic marker for hepatocellular carcinoma | YU-YUN SHAO | Hepatology international | 0 | 0 | |
2022 | Anti-PD-1 combined sorafenib versus anti-PD-1 alone in the treatment of advanced hepatocellular cell carcinoma: a propensity score-matching study | Chen S.-C.; Huang Y.-H.; Chen M.-H.; Hung Y.-P.; Lee R.-C.; YU-YUN SHAO ; Chao Y. | BMC Cancer | 8 | 6 | |
2022 | Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma | Lee, Jan-Mou; Hung, Yi-Ping; Chou, Kai-Yuan; Lee, Cheng-Yun; Lin, Shian-Ren; Tsai, Ya-Han; Lai, Wan-Yu; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; Chao, Yee | Frontiers in medicine | 0 | 0 | |
2022 | Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma | YU-YUN SHAO ; HUNG-YANG KUO ; YUNG-MING JENG ; YAO-MING WU ; HSIU-PO WANG ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | BMC cancer | 2 | 2 | |
2022 | Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety | YU-YUN SHAO ; Feng Y.-H.; Yen C.-J.; Yang T.-S.; YING-CHUN SHEN ; Chao Y.; Chen J.-S.; Su C.-Y.; Chen W.-J.; Hsiang H.-L.; CHIH-HUNG HSU | Journal of the Formosan Medical Association | 2 | 1 | |
2013 | Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: A multicenter phase II study | CHIH-HUNG HSU ; Kang Y.K.; Yang T.-S.; CHIA-TUNG SHUN ; YU-YUN SHAO ; Su W.-C.; Sandoval-Tan J.; Chiou T.-J.; Jin K.; CHIUN HSU ; ANN-LII CHENG | Oncology (Switzerland) | 39 | 40 | |
2023 | Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants | YU-YUN SHAO ; Ho, Ching-Liang; Chang, Cheng-Shyong; Chang, Chia-Lun; Lee, Jen-Kuang; Lin, Hung-Ju; Hsiao, Hui-Hua; Chao, Ta-Chung; Lin, Ching-Yeh; Liaw, Chuang-Chi | Acta Cardiologica Sinica | 1 | 1 | |
2010 | Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions | YU-YUN SHAO ; Hu F.-C.; JIN-TUNG LIANG ; Chiu W.-T.; ANN-LII CHENG ; CHIH-HSIN YANG | Journal of the Formosan Medical Association | 26 | 23 | |
2014 | Clinical activity of metronomic chemotherapy in liver cancers | YU-YUN SHAO ; ANN-LII CHENG ; CHIH-HUNG HSU | Metronomic Chemotherapy: Pharmacology and Clinical Applications | 0 | 0 | |
2014 | Clinical characteristics of advanced hepatocellular carcinoma patients with prolonged survival in the era of anti-angiogenic targeted-therapy | LI-CHUN LU ; YU-YUN SHAO ; Chan S.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | 10 | |
2015 | Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma | BIN-CHI LIAO ; YU-YUN SHAO ; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN ; Kuo R.N.; Lai C.-L.; KUO-HSING CHEN ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Clinical Lung Cancer | 11 | 8 | |
2013 | Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer | YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; Chen H.-M.; Kuo R.; CHIH-HSIN YANG ; Lai M.-S. | European Journal of Cancer | 20 | 18 | |
2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
2021 | Correspondence to: Management of venous thromboembolisms: Part II. The consensus for pulmonary embolism and updates | YU-YUN SHAO ; HUNG-JU LIN | Acta Cardiologica Sinica | 2 | 2 | |
2016 | Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression | CHIUN HSU ; LIANG-IN LIN ; Cheng, Yu-Che; Feng, Zi-Rui; YU-YUN SHAO ; ANN-LII CHENG ; DA-LIANG OU | Clinical Cancer Research | 39 | 39 | |
2022 | Cyclin-Dependent Kinase 9 Inhibition as a Potential Treatment for Hepatocellular Carcinoma | YU-YUN SHAO ; Hsu, Hung-Wei; Wo, Rita Robin; Wang, Han-Yu; ANN-LII CHENG ; CHIH-HUNG HSU | Oncology | 0 | 0 | |
2016 | Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice | YI-HSIN LIANG ; YU-YUN SHAO ; BIN-CHI LIAO ; Lee, Ho-Sheng; CHIH-HSIN YANG ; Chen, Ho-Min; CHUN-JU CHIANG ; ANN-LII CHENG ; Lai, Mei-Shu | Journal of Cancer | 7 | 6 | |
2018 | Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS | Chiu, Huai Hsuan; Liao, Hsiao Wei; YU-YUN SHAO ; YEN-SHEN LU ; CHING-HUNG LIN ; Tsai, I. Lin; CHING-HUA KUO | Analytica Chimica Acta | 39 | 38 | |
2012 | Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma | Shau W.-Y.; YU-YUN SHAO ; Yeh Y.-C.; ZHONG-ZHE LIN ; Kuo R.; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 31 | 32 | |
2019 | Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma | LI-CHUN LU ; CHIUN HSU ; YU-YUN SHAO ; Chao Y.; Yen C.-J.; I-LUN SHIH ; Hung Y.-P.; Chang C.-J.; Ying-Chun Shen ; JHE-CYUAN GUO ; TSUNG-HAO LIU ; CHIH-HUNG HSU ; ANN-LII CHENG | Liver Cancer | 42 | 42 | |